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Abstract 
Background 
Atorvastatin and metformin are known energy restricting mimetic agents that act synergistically 
to produce molecular and metabolic changes in advanced prostate cancer (PCa). This trial seeks 
to determine whether these drugs favourably alter selected parameters in men with clinically-
localized, aggressive PCa. 
Methods/design 
This prospective phase II randomized, controlled window trial is recruiting men with clinically 
significant PCa, confirmed by biopsy following multiparametric MRI and intending to undergo 
radical prostatectomy.  Ethical approval was granted by the Royal Brisbane and Women‟s 
Hospital Human and The University of Queensland Medical Research Ethics Committees.  
Participants are being randomized into four groups: metformin with placebo; atorvastatin with 
placebo; metformin with atorvastatin; or placebo alone. Capsules are consumed for 8 weeks, a 
duration selected as the most appropriate period in which histological and biochemical changes 
may be observed while allowing prompt treatment with curative intent of clinically significant 
PCa. At recruitment and prior to RP, participants provide blood, urine and seminal fluid. A 
subset of participants will undergo 7Tesla magnetic resonance spectroscopy to compare 
metabolites in-vivo with those in seminal fluid and biopsied tissue.  
The primary end point is biochemical progression, defined using biomarkers (serum prostate 
specific antigen; PCA3 and citrate in seminal fluid and prostatic tissue). Standard pathological 
assessment will be undertaken alongside quality of life and psychosocial outcome assessments.  
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Discussion 
This study is designed to assess the potential synergistic action of metformin and atorvastatin on 
PCa tumour biology. The results may determine simple methods of tumour modulation to reduce 
disease progression. 
 
Keywords 
Prostate cancer; atorvastatin; metformin; clinical trial; biomarkers; metabolomics 
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1. INTRODUCTION  
Aggressive prostate cancer (PCa)
1
 cells increase glucose uptake and glycolysis under 
normoxic conditions (the Warburg effect [1]) producing glycolytic intermediates that also 
feed biosynthesis and PCa proliferation. [2, 3]. Metformin reduces glucose oxidation to 
increase glutamine metabolism and cell death while inhibiting metastatic behaviour. 
Epidemiological evidence suggests metformin use is associated with reduced risks of many 
cancers, including PCa [4, 5] with reduced hyperinsulinaemia by metformin in advanced PCa 
potentially improving androgen deprivation therapy (ADT) response [6].
 
When statins are 
combined with metformin, further reduction in PCa progression and improved clinical 
outcomes have been reported, indicating a potential additive or synergistic effect to this 
medication combination [7-9].  Statins reduce cholesterol and mevalonic acid biosynthesis, 
with in vitro evidence that statins slow testosterone synthesis by inhibiting pre-cursor 
molecule transport, improving ADT response [10]. Hypercholesterolaemia is associated with 
high risk PCa [11] and androgen-independent PCa metastasis [12] with statin use associated 
with lower prostate specific antigen (PSA) levels, percentage positive biopsies and fewer 
cases of advanced and fatal disease [8]. Lipophilic statins such as atorvastatin also inhibit 
                                                          
1 Abbreviations: ADT – androgen deprivation therapy; bEvo – biochemical progression; DSS - 4,4-dimethyl-4-silapentane-1-sulfonic 
acid-d6; DFTMP – difluorotrimethylsilanylphosphonic acid; ERMA – energy restriction mimetic agents; FID – free induction decay; 
GPC – glycerophosphocholine; ISUP – International Society of Urological Pathology; mpMRI – multiparametric magnetic resonance 
imaging; MRS – magnetic resonance spectroscopy; NMR – nuclear magnetic resonance; OPLS – orthogonal projections to latent 
structures; PBS – phosphate buffered saline; PCa – prostate cancer; PCA3 – prostate cancer antigen 3;  PLS – partial least squares; PSA 
– prostate specific antigen; RBWH – Royal Brisbane and Women‟s Hospital; RP – radical prostatectomy; SF – seminal fluid, SF-36 – 
Short Form Health Survey 36 
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PCa cell migration to bone marrow stroma [13], however benefit in reducing biochemical 
recurrence, remains uncertain [14].
  
Medication safety profiles of metformin and atorvastatin are favourable, with significant side 
effects rarely observed. Concern for metformin regarding lactic acidosis is reserved for 
patients with significant comorbidities (chronic renal failure, congestive cardiac failure) [15]. 
Large cohorts consuming statins report rhabdomyolysis in up to 11 per 100,000 person-years 
[16]. The use of metformin as a neoadjuvant agent for 4-12 weeks by Joshua and colleagues 
was well tolerated and demonstrated a 10% reduction in PSA, 6.5% reduction in IGF-1 and 
5% reduction in BMI [17]. Such ideal drug tolerability and favourable clinical effects 
supports their adjunctive use in localized prostate cancer without need for a phase I 
controlled trial in this context. 
Metformin and atorvastatin may influence malignant metabolic transformation in the 
prostate, known to favour ATP production and fatty acid synthesis, by shifting citrate, 
detectable in seminal fluid (SF) [18-20]. Markers, such as prostate cancer antigen 3 (PCA3), 
improve PCa detection and disease monitoring but may vary with epigenetic and exogenous 
stimuli [21, 22].  
Initially promising findings by Joshua and colleagues demonstrated significant changes in 
molecular markers following neoadjuvant metformin therapy prior to RP [17]. These 
medications are also being explored in Metformin Active Surveillance Trial (MAST) Study 
(NCT01864096) in delaying pathologic disease progression. Thus, exploring the role of 
energy restriction mimetic agents (ERMAs) represents an exciting development in managing 
men with PCa. However, before atorvastatin and metformin can be entertained for use in 
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patients with early PCa, their potential demonstrable beneficial effects with respect to 
tumour parameters need to be evaluated objectively.  
The primary aim of this study is to determine whether these drugs by themselves and 
together, favourably alter selected parameters in a group of clinically-localized, aggressive 
PCas.  
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2. MATERIALS AND METHODS 
2.1 Study design 
This is a prospective randomized, double-blinded controlled phase II window trial designed to 
determine the efficacy on biochemical progression of atorvastatin and metformin, in isolation and 
together, in a population of men with early, clinically significant PCa. In addition, the effect of 
these drugs on PCa biology will be assessed in a population not previously studied in this respect 
whilst these men await definitive treatment by radical prostatectomy (RP), in accordance with a 
phase II window trial design [23]. Men with an elevated PSA who have a multiparametric 
magnetic resonance imaging (mpMRI) examination that demonstrates a PI-RADS 4 or 5 lesion 
and who, at consultation, express an intention to proceed to RP should biopsy confirm the 
suspicion of high-risk PCa, will be approached to enter the study. Our current practice includes in 
depth counselling prior to biopsy in order to ascertain the benefits to the patient in investigating 
for PCa. This includes outlining the biopsy and treatment process, with treatment options of 
surgery, radiotherapy, active surveillance or watchful waiting all discussed. Following written 
informed consent and randomisation by the manufacturing pharmacy (QPharm) to ensure 
clinician and participant blinding, four study groups are being examined, as outlined in Figure 1.   
The protocol is designed and reported according to the SPIRIT guidelines [24]. Participants will 
provide blood, urine and SF after 48hrs abstinence of sexual activity. Blood and SF samples will 
be used to determine biomarkers of interest as defined by the primary and secondary endpoints. 
Further exploratory analyses will be conducted as outlined in order to determine biochemical 
effects of these medications in this patient cohort. Prior to giving specimens, a subset of 
participants, selected by a sub-randomisation process, will opportunistically undergo a further 
mpMRI with MRS using a 7 Tesla machine at the University of Queensland Centre for Advanced 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
10 
 
Imaging. Here, we will assess the metabolic profile of participants prostates in-vivo, for 
comparison with those seen in seminal fluid in vitro, and ascertain if superior imaging is 
provided by this machine. Participants will then undergo transperineal prostate biopsy targeting 
lesions of interest (cognitive biopsies) detected by pre-trial mpMRI, in addition to systematic 
whole gland biopsies using a template as per the local department protocol. Biopsy samples from 
index lesions and from non-index lesion areas will be taken for research purposes and stored for 
subsequent molecular and nuclear magnetic resonance (NMR) analysis.  
Participants will undergo 8 weeks of capsule consumption, as this duration was determined to be 
most appropriate in which histological and biochemical changes may be observed while allowing 
prompt treatment with curative intent of clinically significant PCa. Non-invasively obtained 
participant samples will be collected again and mpMRI with magnetic resonance spectroscopy 
(MRS) will be repeated (for those previously randomized to have these investigations). The 
reason for allocating only a limited number of participants for mpMRI and MRS with the 7 Tesla 
machine is cost. The biomarker kinetic changes following biopsy are poorly described, however 
we expect these will be minimally affected by biopsy artefacts with 8 weeks of treatment and 
healing. Latifoltojar and colleagues examined changes in mpMRI parameters following biopsy 
and described a return to baseline apparent diffusion coefficient (ADC) parameters 1 month post 
biopsy [25]. The effects of biopsy on MRS parameters are currently unknown and will be 
examined in this study.  
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Figure 1: Flow chart of study design, incorporating timing of specimen collection, imaging and capsule distribution. 
Ethical approval has been obtained from the Royal Brisbane and Women‟s Hospital (RBWH) 
Human Research Ethics Committee (Approval no. HREC/14/QRBW/153 together with 
HREC/09/QRBW/320, HREC/09/QRBW/305 and 1995/088B) and The University of 
Queensland Medical Research Ethics Committee (Approval no. 2014000944 together with 
2006000262) using the National Ethical Application Form. Specialist clinicians are overseeing 
all aspects of management through our established team. This trial has been registered in the 
Australian New Zealand Clinical Trials Registry (Registration number: 
ACTRN12615000571572). 
Consent to participate in the trial is being obtained from treating urologists or the Trial 
Coordinator (RM). This process also includes provision for storage and future use of clinical data 
and biological specimens. Database access is password-protected and limited to the Trial 
Coordinator (RM) who will then provide information as necessary to the other investigators. The 
Group 1 (n = 20) 
Metformin + 
placebo 
Group 2 (n = 20) 
Atorvastatin + 
placebo 
Group 3 (n = 20) 
Metformin + 
atorvastatin 
Group 4 (n = 20) 
Placebo only 
Informed consent obtained: mpMRI & MRS for a subset of participants selected by further 
randomisation 
Blood, urine and SF samples provided. 
Patient randomised and prostate biopsy performed. 
8 week treatment duration with retrieval of any remaining capsules 
Repeat mpMRI & MRS (for a subset), blood, urine and SF sample provision by all participants 
Radical prostatectomy and histopathological analysis with biopsies for research 
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database will be stored on a secure internal (UQ) server. At the conclusion of the trial, data 
access will be limited to the Trial Coordinator (RM) and relevant Principal Investigators (MJR, 
RAG). 
Adverse events are being monitored by the Trial Coordinator (RM), who contacts participants by 
telephone on two occasions during the trial to ensure satisfaction and determine the presence of 
any medication side-effects, or other difficulties. In addition, participants are instructed to 
contact the trial coordinator should they have any concerns or difficulties at other times during 
the trial. Further reports to the participants treating urologists and general practitioners, as well as 
relevant hospitals will be included and promptly assessed in detail.  
Untoward events are being determined by participant experiences of new symptoms during the 
study period, as well as routine monitoring using pathology tests, and the results of any other 
investigations prompted by other health professionals (e.g. general practitioners, emergency 
department clinicians) during the study period. The Clavien system is being used to document 
any adverse effects reported, while study questionnaires are also being monitored for participant 
satisfaction. Adverse outcomes and trial conduct are regularly audited and discussed with the 
relevant ethics representatives. 
The funding source had no involvement in study design; in the collection, analysis and 
interpretation of data; in the writing of the report; and in the decision to submit the article for 
publication. 
2.2 Study population and Recruitment 
Participants are being recruited from the RBWH Urology Outpatient clinic and specialist private 
practices in Brisbane, Queensland. Clinicians identify men as having clinically significant PCa 
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on the basis of prostate imaging with mpMRI and who intend to proceed to RP. Following 
informed consent, those fulfilling all inclusion criteria and no exclusion criteria are entered into 
the randomization process. Recruitment is promoted by treating urologists discussing the study 
with eligible participants. 
Inclusion criteria  
 suspected of having high-risk PCa on the basis of mpMRI (PIRADS 4/5 lesions), with 
clinically-localized PCa and who intend to proceed to RP following confirmation of their 
disease as high-risk following biopsies;  
 able to provide informed consent (written and verbal) in English;  
 considered by their urologist that involvement in the research programme/ involvement in 
the study is considered to be their best interests, for appropriate selection of patients who 
are likely to benefit from treatment;  
 prepared and able to provide a specimen of SF for monitoring before biopsy and at the 
completion of treatment, just before RP;  
 willing to provide urine and serum samples prior to biopsy and again before RP  
 able to lie flat and willing to undergo mpMRI/MRS scanning on two occasions during the 
trial period with no previous or current history of claustrophobia; 
 normal fasting blood glucose, kidney and liver function tests; 
Exclusion criteria 
 previous history of head injury, dementia, psychiatric illness or concurrent cancer;  
 regular administration of any lipid-lowering medication or blood-glucose lowering drugs 
 prior experience of any adverse effects with lipid or glucose-lowering drugs;  
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 currently taking drugs known or thought to have an interaction with metformin and 
atorvastatin; 
 previous ingestion of a 5-alpha reductase inhibitor drug; 
 known co-morbidities that would contraindicate commencement of metformin or 
atorvastatin, such as chronic kidney disease, congestive heart failure, liver disease.  
2.3 Randomisation and allocation concealment 
Following enrolment, participants are randomized using a centralized database by an external 
research pharmaceutical organisation (QPharm Pty Ltd), which is experienced in participation 
and formulation of drugs for its own and other clinical trials. The randomization is stored and 
concealed by QPharm, resulting in blinding of clinicians and participants to study medications. 
Unblinding will be permissible in the event of an adverse event resulting in cessation of 
medication use, with liaison between the investigators, QPharm and the participant. All 
medications are identical in appearance to maintain blinding during medication ingestion. 
2.4 Intervention 
Participants are randomized into one of the four study groups:  
1) metformin 500 mg twice a day with placebo once a day;  
2) atorvastatin 20 mg once a day with placebo twice a day;  
3) metformin 500 mg twice a day with atorvastatin 20 mg once a day;  
4) placebo three times a day.  
All capsules have been formulated by QPharm Pty Ltd to appear identical in order to comply 
with blinding for participants and investigators.  
2.5 Outcome measures 
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Primary endpoint 
The primary end point is serum PSA “biochemical evolution” (bEvo), defined as an increase 
inSerum PSA prior to surgery and following 8 weeks of treatment from baseline measurement of 
20% (based on values of reported studies [17, 26, 27]). These studies were used instead of those 
from larger observational studies [28, 29] as the observational studies had a low (25 – 30%) 
proportion of clinically significant PCa. The term “biochemical progression” is intended for this 
specific definition and different from “biochemical recurrence” commonly used in the post-
treatment scenario. 
Secondary endpoints  
Secondary endpoints that are being assessed opportunistically are biochemical progression for 
seminal fluid-based  biomarkers PCA3:PSA and citrate, defined for each biomarkers as follows:  
a) PCA3:PSA measured in seminal fluid: Increase from baseline measurement by 20% 
(based on improved all-cause and cancer-specific survival estimates[30]). 
b) Citrate measured in seminal fluid and prostatic biopsies at the time of transperineal 
biopsies and the prostate ex-vivo after RP as well as MRS: Increase from baseline 
measurement of 30% (based on serum citrate association with aggressive prostate cancer 
[19]). 
These biochemical markers are being preferentially assessed ahead of tissue histological markers 
on the basis that biochemical effects precede histological change, known as the „field effect‟ in 
cancer biology [31], and are thus more likely to be detected in vitro using seminal fluid and in 
vivo using MRSI.  
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Clinical Data Collection 
Clinical data will be obtained by participating urologists and the Trial Coordinator (RM), who 
contacts participants by telephone on at least two occasions during the trial to ensure participant 
satisfaction and determine the presence of any side-effects or other difficulties. The Trial 
Coordinator is experienced in the data collection tools being used. Data will be collected onto a 
CAISIS database, used in our randomized, controlled study of open and robotic prostatectomy 
[32, 33] and with which we are familiar.  
Assessment and Follow-up 
Participants are being assessed for inclusion upon enrolment for prostate biopsy. Those whose 
biopsies do not include any Gleason 4 or 5 tumour do not receive drug and do not take any 
further part in the study. Participants continuing receive medication, as per randomization 
protocol, and are placed on the waiting list for surgery which is planned for 8 weeks after their 
biopsies. 
Serum investigations used clinically include total PSA (Abbott Architect® assay) and free-total 
PSA estimations as well as serum testosterone and metabolic screening (serum biochemical and 
lipoprotein profiles). Blood tests will all be performed according to standard assays by Sullivan 
& Nicolaides Pathology in addition to glycoslylated PSA quantified as previously described [34].  
The intended duration from diagnosis and treatment is 8 weeks, with assessments performed 
prior to biopsies and again just before RP. mpMRI and MRS will be assessed by IB, NK and 
ML. Biopsy and RP slides will be reviewed by specialized uropathologists (JP-K, JDP, MLTHS) 
with reference to the 2014 International Society of Urological Pathology (ISUP) classification 
[35] for continuity and expert interpretation. Standard parameters for biopsies (total number of 
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cores, number and percentage of positive cores, Gleason/ISUP score) and RP specimens (gland 
size, margin status, extracapsular status, pathological stage, Gleason score) are being reported. 
Surgical follow-up is being determined by the treating urologist with follow-up assessments 
performed at these appointments until 24 months post-operatively.  
Technical details regarding biological sampling and storage as well as molecular and 
metabolomic investigations are outlined in the Supplementary Material. 
2.7 Sample size and statistical analysis  
Sample sizes were based on a randomized selection design with the aim of achieving a 80% 
probability that the best schedule produced the highest observed response rate [36-38]. We took 
the expected baseline freedom from biochemical progression rate for the placebo schedule to be 
80% based on results reported for the serum PSA biomarker [27]. We estimate that we need to 
study 20 participants per schedule, to have a 80% probability of selecting the schedule that has a 
true freedom from biochemical progression rate that is at least 15% higher assuming this is the 
minimal practically significant difference. This calculation can be verified through the online 
calculator from the Center for Clinical Research and Biostatistics of the Chinese University of 
Hong Kong (https://www2.ccrb.cuhk.edu.hk/stat/phase2/Randomized.htm). We were unable to 
suitably estimate the proportion of men who would be enrolled with a negative biopsy result and 
so are continuing to recruit until the sample size is achieved. 
Differences in categorical variables between groups will be tested using chi squared analysis 
while continuous variables will be compared using two-sample t tests. Univariate analysis will be 
performed using the binary bEvo variable as the outcome and intervention schedule category as 
the predictor using a GLM with a Poisson family, log link and robust error variances in order to 
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generate the relative risk. Multivariable analysis will also be performed using a similar GLM to 
determine the independence of the schedule of treatment from other relevant explanatory 
variables. The latter will be included in the multivariable model if they are found to be associated 
with outcome (P<0.2) on univariate analysis. Link specification will be tested using the squared 
linear predictor while the goodness of fit of the model will be evaluated by the ability of the 
linear predictor from the model to classify participants into progressors and non-progressors (i.e., 
its predictive performance) will be evaluated using the C statistic, a term equivalent to the area 
under a receiver operating characteristic curve for the dichotomous outcome (bEvo). All analysis 
will be done using Stata (StataCorp, College Station, TX) and P<0.05 will be the threshold for 
significance.  
3. DISCUSSION 
Since commencing the study in March 2015, 9 participants have been recruited and 2 have 
completed the treatment and assessment protocols. One man with a mpMRI PI-RADS 4 lesion 
did not have PCa detected with his biopsies. As a consequence his participation in the trial was 
terminated. Compared with recruitment for altruistic SF donation by patients without likelihood 
of personal benefit, recruitment for this study, which includes SF donation as an essential 
requisite, has been much easier but considerable greater difficulty is being experienced 
identifying men who have not been consuming a statin regularly. 
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